First Time Loading...
C

Cyteir Therapeutics Inc
NASDAQ:CYT

Watchlist Manager
Cyteir Therapeutics Inc
NASDAQ:CYT
Watchlist
Price: 3.01 USD Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

CYT Price Targets Summary
Cyteir Therapeutics Inc

Wall Street analysts forecast CYT stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYT is 3 USD .

CYT Lowest Forecast
Wall Street Target
Not Available
CYT Average Forecast
Wall Street Target
3 USD
0% Downside
CYT Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
3 USD
0% Downside
Highest
Price Target
Not Available

CYT Last Price Targets
Cyteir Therapeutics Inc

The latest public price target was made on Feb 3, 2023 by Unknown Analyst from Morgan Stanley , who expects CYT stock to drop by 34% over the next 12 months. You can read more about this price target by viewing the article on Benzinga.

Analyst Price Target Date Article
Unknown Analyst
Morgan Stanley
2 USD
Downside 34%
1 year ago
Feb 3, 2023
Morgan Stanley Downgrades Cyteir Therapeutics to Underweight, Lowers Price Target to $2
Benzinga
Unknown Analyst
Morgan Stanley
Price Target 2 USD
Upside/Downside 34%
View Source
Cyteir Therapeutics Inc Competitors:
Price Targets
CUV
Clinuvel Pharmaceuticals Ltd
79% Upside
ORY
Oryzon Genomics SA
234% Upside
ABBV
Abbvie Inc
16% Upside
P
214450
PharmaResearch Co Ltd
37% Upside
CUV
Clinuvel Pharmaceuticals Ltd
79% Upside
ORY
Oryzon Genomics SA
234% Upside
ABBV
Abbvie Inc
16% Upside
P
214450
PharmaResearch Co Ltd
37% Upside
C
688276
Changchun BCHT Biotechnology Co
62% Upside
KOD
Kodiak Sciences Inc
23% Upside
9969
InnoCare Pharma Ltd
37% Upside
DCPH
Deciphera Pharmaceuticals Inc
3% Downside

Revenue
Forecast

Revenue Estimate
Cyteir Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cyteir Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cyteir Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
CYT intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYT stock valuation using valuation multiples.
Wall Street Estimates
CYT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYT's stock price target?
Price Target
3 USD

According to Wall Street analysts, the average 1-year price target for CYT is 3 USD .

ALPHA SPREAD
Join more than 133,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.